AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Roger Yu
Oct. 15--Shares of Alcon Inc. fell 11 percent Thursday after the company revealed that a clinical test shows its much-anticipated drug for treating blindness hasn't outperformed a rival product already on the market.
In the one-year study, Alcon, a Swiss maker of eye-care products with its U.S. headquarters in Fort Worth, compared its drug, Retaane, with Novartis AG's Visudyne.
The percentage of patients who maintained vision when treated with Alcon's drug was 45 percent, compared to 49 percent for those using Visudyne.
"These overall results indicate that the two therapies are not statistically different from each ...